Efficacy and Safety of Ipragliflozin in Patients With Type 2 Diabetes: ASSIGN-K Study

Background: null Sodium null glucose cotransporter 2 (SGLT2) inhibitors achieve good glycemic null control in patients with type 2 diabetes, as well as reducing body null weight and blood pressure. However, no large-scale clinical studies of null SGLT2 inhibitors have been performed in Japan. The ASSIGN-K study null investigated the efficacy and safety of ipragliflozin, a selective SGLT2 null inhibitor, in routine clinical practice. null null...